Vistagen Announces European Patent Office Intention To Grant New PH80 Nasal Spray Patent For The Treatment Of Migraine
Portfolio Pulse from Benzinga Newsdesk
Vistagen (NASDAQ:VTGN) announced that the European Patent Office (EPO) intends to grant a patent for the treatment of migraine using its PH80 nasal spray. The patent will not expire until at least 2040. The U.S. Patent and Trademark Office (USPTO) recently granted a related U.S. patent for the same treatment.
June 13, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen's PH80 nasal spray receives European Patent Office's intention to grant a patent for migraine treatment, following a recent US patent approval.
The intention to grant a patent for Vistagen's PH80 nasal spray by the European Patent Office, along with the recent US patent approval, indicates a positive outlook for the company's product. This news may lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100